Skip to main content

Neuroendocrine Tumor clinical trials at UC Cancer
5 research studies open to eligible people

  • Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)

    open to eligible people ages 18 years and up

    This is an open-label, multicenter, global Phase 2 basket study of entrectinib (RXDX-101) for the treatment of patients with solid tumors that harbor an NTRK1/2/3, ROS1, or ALK gene fusion. Patients will be assigned to different baskets according to tumor type and gene fusion.

    at UC Irvine UCSD UCSF

  • Cabozantinib S-malate in Treating Patients With Neuroendocrine Tumors Previously Treated With Everolimus That Are Locally Advanced, Metastatic, or Cannot Be Removed by Surgery

    open to eligible people ages 18 years and up

    This randomized phase III trial studies cabozantinib S-malate to see how well it works compared with placebo in treating patients with neuroendocrine tumors previously treated with everolimus that have spread to nearby tissues or lymph nodes, have spread to other places in the body, or cannot be removed by surgery. Cabozantinib S-malate is a chemotherapy drug known as a tyrosine kinase inhibitor, and it targets specific tyrosine kinase receptors, that when blocked, may slow tumor growth.

    at UC Davis UCSF

  • Pembrolizumab in With Liver-Directed or Peptide Receptor Radionuclide Therapy in Neuroendocrine Tumors With Metastases

    open to eligible people ages 18 years and up

    This pilot phase II trial studies how well pembrolizumab in combination with liver-directed therapy or Peptide Receptor Radionuclide Therapy (PRRT) works in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver. Monoclonal antibodies, such as pembrolizumab, may interfere with the ability of tumor cells to grow and spread. Liver-directed therapies such as, transarterial embolization (TAE), yttrium-90 microsphere radioembolization (RE), and cryoablation may help to shrink tumors that are not being directly targeted. Somatostatin receptor positive (SSTR+) well- diferentiated neuroendocrine tumors (WD-NETs) may benefit from treatment with peptide receptor radionuclide therapy (PRRT) using 177Lu DOTATATE. Giving pembrolizumab in combination with liver-directed therapy or PRRT may work better in treating patients with well-differentiated metastatic neuroendocrine tumors and symptomatic and/or progressive tumors that have spread to the liver.

    at UCSF

  • Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Patients With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors

    open to eligible people ages 18 years and up

    This is a Phase 1/2, open-label, first-in-human (FIH) study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antineoplastic activity of pralsetinib (BLU-667) administered orally in patients with medullary thyroid cancer, RET-altered NSCLC and other RET-altered solid tumors.

    at UC Irvine

  • Randomized Embolization Trial for NeuroEndocrine Tumor Metastases To The Liver

    open to eligible people ages 18 years and up

    The primary aim of this trial is to estimate the duration of hepatic progression-free survival (HPFS) in participants treated with bland embolization (BE), transcatheter arterial Lipiodol chemoembolization (TACE), and embolization by drug-eluting beads (DEB). The primary hypothesis is that chemoembolization will be nearly twice as durable as bland embolization; thatis, the hazard ratio for HPFS will be 1.76 or better.

    at UCSF

Last updated: